Comparing drug combinations for ulcerative colitis and Crohn's disease
Part of Digestive system clinical trials.
This trial compares how well different combinations of drugs calm inflammation in the gut compared to single drugs. It uses tissue samples taken during a colonoscopy to see which approach works best for people with inflammatory bowel disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must be willing and able to follow the study steps and sign a consent form.
- If you have ulcerative colitis or Crohn's disease, your disease must be active (moderate to severe) and your doctor must be planning to start you on a new biologic or similar medication.
- If you do not have IBD, you may qualify if you have irritable bowel syndrome, or if you are having a routine colonoscopy for colon cancer screening and have no signs of inflammation.
- You cannot take part if you are pregnant or breastfeeding.
- You must not have any medical reason that makes a colonoscopy unsafe for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at people with Crohn's disease or ulcerative colitis who have already tried and failed at least one advanced medication (like a biologic or small molecule drug). If you are starting a new advanced therapy, researchers will track how well it works for you.
This trial tests new therapies for people with moderate to severe Crohn's disease or ulcerative colitis. It may help if your standard treatments aren't working well enough.
This study looks at people with Crohn's disease or ulcerative colitis who are having a colonoscopy to check for abnormal cells in the colon. The goal is to learn more about these growths and how likely they are to become cancer over time, which could help improve future monitoring and treatment.
This study tests a new way to monitor ulcerative colitis using stool tests and colonoscopy to detect early signs of cancer. It may help doctors manage long-term ulcerative colitis more safely.
Researchers want to see if taking two medications together (upadacitinib and vedolizumab) works better than taking just upadacitinib alone for people with moderate to severe ulcerative colitis. This is a real-world study, meaning it looks at patients being treated in normal medical practice.
This study collects blood, stool, tissue, and health information from people with inflammatory bowel disease (IBD), their relatives, and healthy volunteers to find patterns that may help diagnose or treat IBD better in the future.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.